@article{JGO11972,
author = {Pierre Annede and Thomas Seisen and Caroline Klotz and Renaud Mazeron and Pierre Maroun and Claire Petit and Eric Deutsch and Alberto Bossi and Christine Haie-Meder and Cyrus Chargari and Pierre Blanchard},
title = {Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {1},
year = {2017},
keywords = {},
abstract = {Background: Few studies with contradictory results have been published on the safety of pelvic radiation therapy (RT) in patients with inflammatory bowel disease (IBD).
Methods: From 1989 to 2015, a single center retrospective analysis was performed including all IBD patients who received pelvic external beam radiation therapy (EBRT) or brachytherapy (BT) for a pelvic malignancy. Treatment characteristics, IBD activity and gastrointestinal (GI) toxicity were examined.
Results: Overall, 28 patients with Crohn’s disease (CD) (n=13) or ulcerative colitis (n=15) were included in the present study. Median follow-up time after irradiation was 5.9 years. Regarding IBD activity, only one and two patients experienced a severe episode within and after 6 months of follow-up, respectively. Grade 3/4 acute GI toxicity occurred in 3 (11%) patients, whereas one (3.6%) patient experienced late grade 3/4 GI toxicity. Only patients with rectal IBD location (P=0.016) or low body mass index (BMI) (P=0.012) experienced more severe IBD activity within or after 6 months following RT, respectively.
Conclusions: We report an acceptable tolerance of RT in IBD patients with pelvic malignancies. Specifically, a low risk of uncontrolled flare-up was observed.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/11972}
}